Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Dementia01:30

Dementia

141
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
141
这页已由机器翻译。其他页面可能仍然显示为英文。View in English
  1. 首页
  2. 研究领域
  3. 生物医学和临床科学
  4. 免疫学
  5. 自体免疫性
  6. 在早期症状性阿尔茨海默氏症中使用多纳尼马布: Trailblazer-alz 2随机临床试验

在早期症状性阿尔茨海默氏症中使用多纳尼马布: TRAILBLAZER-ALZ 2随机临床试验

John R Sims1, Jennifer A Zimmer1, Cynthia D Evans1

  • 1Eli Lilly and Company, Indianapolis, Indiana.

JAMA
|July 17, 2023

相关实验视频

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.9K

在PubMed 上查看摘要

概括
此摘要是机器生成的。

作为阿尔茨海默病的抗体治疗药物,多纳纳马布在早期症状患者中显著减缓了疾病的进展. 这种阿尔茨海默病药物在低/中和联合tau病理组中都表现出有效性.

科学领域:

  • 神经学
  • 免疫疗法
  • 阿尔茨海默病的研究

背景情况:

  • 对阿尔茨海默病的有效治疗方法有限.
  • 这是一种阿尔茨海默病的标志.

研究的目的:

  • 评估donanemab在早期症状阿尔茨海默病患者中的疗效和安全性.
  • 评估donanemab对认知和功能衰退的影响.

主要方法:

  • 第三阶段,多中心,随机,双盲,安慰剂对照试验.
  • 1736名患有早期阿尔茨海默氏症的参与者接受了多纳马布或安慰剂静脉注射72周.
  • 主要结局:在76周后,综合阿尔茨海默病评分表 (iADRS) 的得分发生变化.

主要成果:

  • 在低/ 中等tau和联合tau病理组中,donanemab显著减缓了临床进展.
  • 在24个封闭结果中,有23个结果具有统计学意义.
  • 与粉样蛋白相关的成像异常 (ARIA) 发生在多纳马布组的24. 0%,与安慰剂组的2. 1%相比.

结论:

  • 对于早期症状性阿尔茨海默病,多纳纳是一种有前途的治疗选择.

相关实验视频

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.9K
  • 这种药物显著减缓了临床进展,特别是在具有特定tau病理特征的患者中.
  • 需要对ARIA进行进一步的研究和监测.